RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions
RAPT Stock Forecast
RAPT Therapeutics stock forecast is as follows: an average price target of $30.71 (represents a 2691.82% upside from RAPT’s last price of $1.10) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
RAPT Price Target
The average price target for RAPT Therapeutics (RAPT) is $30.71 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $2.00. This represents a potential 2691.82% upside from RAPT's last price of $1.10.
RAPT Analyst Ratings
According to 7 Wall Street analysts, RAPT Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for RAPT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (42.86%), 4 'Hold' (57.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
RAPT Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | Thomas Smith | Leerink Partners | $2.00 | $1.74 | 14.94% | 81.82% |
| Nov 12, 2024 | Alex Thompson | Stifel Nicolaus | $2.00 | $1.74 | 14.94% | 81.82% |
| Jan 04, 2023 | - | Guggenheim | $55.00 | $19.82 | 177.43% | 4900.00% |
| Jan 04, 2023 | - | Wells Fargo | $48.00 | $19.50 | 146.15% | 4263.64% |
| Dec 08, 2022 | Edward Tenthoff | Piper Sandler | $33.00 | $16.48 | 100.24% | 2900.00% |
| Dec 01, 2022 | - | Goldman Sachs | $27.00 | $17.68 | 52.71% | 2354.55% |
| Nov 11, 2022 | - | Piper Sandler | $34.00 | $21.98 | 54.69% | 2990.91% |
| Sep 21, 2022 | Zegbeh Jallah | Capital One Financial | $48.00 | $24.17 | 98.59% | 4263.64% |
The latest RAPT Therapeutics stock forecast, released on Nov 12, 2024 by Thomas Smith from Leerink Partners, set a price target of $2.00, which represents a 14.94% increase from the stock price at the time of the forecast ($1.74), and a 81.82% increase from RAPT last price ($1.10).
RAPT Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 2 |
| Avg Price Target | $2.00 | $2.00 | $2.00 |
| Last Closing Price | $1.10 | $1.10 | $1.10 |
| Upside/Downside | 81.82% | 81.82% | 81.82% |
In the current month, the average price target of RAPT Therapeutics stock is $2.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 81.82% increase as opposed to RAPT Therapeutics's last price of $1.10. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 12, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Aug 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 14, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
| May 10, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| May 09, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| May 09, 2024 | Guggenheim | Buy | Hold | Downgrade |
| Feb 21, 2024 | Cantor Fitzgerald | - | Neutral | Downgrade |
| Feb 21, 2024 | Barclays | Overweight | Overweight | Hold |
| Feb 21, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| Jan 04, 2023 | Guggenheim | - | Buy | Initialise |
RAPT Therapeutics's last stock rating was published by Leerink Partners on Nov 12, 2024. The company gave RAPT a "Market Perform" rating, the same as its previous rate.
RAPT Therapeutics Financial Forecast
RAPT Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $641.00K | - | $886.00K | $641.00K | $756.00K | $966.00K | $869.00K | $1.22M | $1.30M | $1.53M | $1.28M | $935.00K |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.84% | - | 3.16% | 2.75% | 0.93% | 1.24% | 0.86% | 1.35% | 1.02% | 1.53% | 1.53% | 0.75% |
RAPT Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. RAPT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $641.00K (Dec 22).
RAPT Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-24.43M | $-21.42M | $-18.64M | $-20.52M | $-17.70M | $-18.42M | $-15.85M | $-16.23M | $451.26K | $-14.08M | $-11.72M | $-12.70M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-67.31K | $-56.00K | $-19.91M | $-162.20K | $-155.63K | $-202.50K | $-15.19M | $-255.28K | $-200.15K | $-166.67K | $-8.86M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-67.31K | $-56.00K | $-15.93M | $-162.20K | $-155.63K | $-202.50K | $-12.15M | $-255.28K | $-200.15K | $-166.67K | $-7.09M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-67.31K | $-56.00K | $-23.89M | $-162.20K | $-155.63K | $-202.50K | $-18.22M | $-255.28K | $-200.15K | $-166.67K | $-10.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 921.96% | 318.18% | 332.77% | 1.03% | 109.11% | 118.37% | 78.29% | 1.07% | -1.77% | 70.35% | 70.34% | 1.43% |
1 analysts predict RAPT's average Quarter EBITDA for Mar 21 to be $-15.19M, with a high of $-12.15M and a low of $-18.22M. This is -3465.35% lower than RAPT Therapeutics's previous annual EBITDA (Dec 20) of $451.26K.
RAPT Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-21.47M | $-20.79M | $-19.46M | $-20.16M | $-17.93M | $-18.65M | $-16.11M | $-16.51M | $-12.73K | $-14.63M | $-12.39M | $-13.14M |
| Avg Forecast | $-19.55M | $-19.56M | $-18.09M | $-18.09M | $-16.53M | $-17.48M | $-18.76M | $-18.77M | $-17.82M | $-22.55M | $-28.00M | $-25.45M | $-26.08M | $-28.73M | $-20.17M | $-25.70M | $-24.20M | $-26.41M | $-15.45M | $-22.54M | $-21.84M | $-22.99M | $-9.17M |
| High Forecast | $-19.55M | $-19.56M | $-18.09M | $-18.09M | $-16.53M | $-17.48M | $-18.76M | $-14.17M | $-15.22M | $-22.55M | $-28.00M | $-25.45M | $-26.08M | $-28.73M | $-16.13M | $-25.70M | $-24.20M | $-26.41M | $-12.36M | $-22.54M | $-21.84M | $-22.99M | $-7.33M |
| Low Forecast | $-19.55M | $-19.56M | $-18.09M | $-18.09M | $-16.53M | $-17.48M | $-18.76M | $-22.31M | $-21.16M | $-22.55M | $-28.00M | $-25.45M | $-26.08M | $-28.73M | $-24.20M | $-25.70M | $-24.20M | $-26.41M | $-18.54M | $-22.54M | $-21.84M | $-22.99M | $-11.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 0.80% | 0.68% | 1.00% | 0.70% | 0.77% | 0.61% | 1.07% | 0.00% | 0.67% | 0.54% | 1.43% |
RAPT Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RAPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
RAPT Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $4.98M | $5.08M | $5.44M | $4.75M | $4.49M | $3.77M | $3.76M | $4.01M | $3.48M | $3.20M | $2.80M | $3.29M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.54% | 3.43% | 4.41% | 4.63% | 1.26% | 1.10% | 0.84% | 1.00% | 0.62% | 0.73% | 0.76% | 0.60% |
RAPT Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RAPT last annual SG&A of $4.98M (Dec 22).
RAPT Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.60 | $-0.62 | $-0.62 | $-0.68 | $-0.61 | $-0.63 | $-0.63 | $-0.66 | $-0.00 | $-0.60 | $-0.51 | $-0.56 |
| Avg Forecast | $-0.50 | $-0.50 | $-0.46 | $-0.47 | $-0.42 | $-0.45 | $-0.48 | $-0.48 | $-0.46 | $-0.58 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| High Forecast | $-0.50 | $-0.50 | $-0.46 | $-0.47 | $-0.42 | $-0.45 | $-0.48 | $-0.36 | $-0.39 | $-0.58 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| Low Forecast | $-0.50 | $-0.50 | $-0.46 | $-0.47 | $-0.42 | $-0.45 | $-0.48 | $-0.57 | $-0.54 | $-0.58 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.92% | 0.84% | 1.00% | 0.92% | 1.01% | 0.93% | 1.10% | 0.00% | 1.07% | 0.86% | 1.14% |
According to undefined Wall Street analysts, RAPT Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RAPT previous annual EPS of $NaN (undefined).
RAPT Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $1.10 | $30.71 | 2691.82% | Hold |
| PMVP | PMV Pharmaceuticals | $1.56 | $18.00 | 1053.85% | Buy |
| ANTX | AN2 Therapeutics | $1.00 | $8.75 | 775.00% | Buy |
| XLO | Xilio Therapeutics | $0.97 | $7.00 | 621.65% | Buy |
| PEPG | PepGen | $4.13 | $29.50 | 614.29% | Buy |
| HOWL | Werewolf Therapeutics | $1.71 | $12.00 | 601.75% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $14.75 | 490.00% | Buy |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| RLAY | Relay Therapeutics | $4.89 | $19.40 | 296.73% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| PLRX | Pliant Therapeutics | $12.32 | $39.71 | 222.32% | Buy |
| ARVN | Arvinas | $23.19 | $71.82 | 209.70% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| STOK | Stoke Therapeutics | $11.88 | $30.60 | 157.58% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| TYRA | Tyra Biosciences | $15.47 | $31.75 | 105.24% | Buy |
| PHVS | Pharvaris | $20.92 | $39.67 | 89.63% | Buy |
| DSGN | Design Therapeutics | $5.76 | $9.67 | 67.88% | Buy |
| CNTB | Connect Biopharma | $1.01 | $1.50 | 48.51% | Buy |
| IKNA | Ikena Oncology | $1.68 | $1.33 | -20.83% | Buy |